As the pandemic still rages in many countries and bruised countries like the UK take their first steps to kick start the economy will we return to our normal reliance on the global supply chains? We business and the public look to buy products made closer to home, Buy British? Will the business be able to sustain the higher costs? The fragility of the global supply chain became very apparent as first China then India closed down and the pharma supply chain to most of the world was under threat. Britain has a pandemic and Brexit to deal with in the coming months and many of the companies who wish to supply the UK will be watching closely to see what the MHRA will announce in the coming months. The NHS keeps the costs of medicines in the UK down and therefore this is another consideration for suppliers is there enough margin, is it worth the effort should they focus on bigger markets. Over the past few months, the key UK suppliers have collaborated to ensure the efficient use of resources and to protect the fragile supply chain to maintain the supply of key medicines, sharing intelligence to ensure active substances and excipients were used wisely to prevent out of stock situations. It is unlikely that the UK will run a buy British for pharmaceuticals as the NHS probably cannot afford to.